Aerobic Exercise for the Improvement of Cognition and Enhancement of Recovery in Post-acute Schizophrenia

Schizophrenia Clinical Trial

Official title:

Aerobic Exercise for the Improvement of Cognition and Enhancement of Recovery in Post-acute Schizophrenia

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03466112
• Other study ID #: Version (V) 2.0 - 30.07.2018
• Status: Completed
• Phase: N/A
• Start date: June 2016
• Est. completion date: December 2021

Study information

• Verified date: February 2022
• Source: Ludwig-Maximilians - University of Munich
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The study investigates the efficacy of aerobic exercise on cognitive performance and brain plasticity in schizophrenia.

Description:

This multi-center, two-arm, parallel-group, randomized placebo-controlled add-on clinical trial investigates the efficacy of aerobic exercise on cognitive performance and brain plasticity in schizophrenia. The aim is the enhancement of recovery with the use of 26 weeks of continuos endurance training (aerobic exercise) with stationary bicycles or a balance and tone program consisting of exercises for flexibility, core strength, balance and relaxation. Followed by a follow-up period of 26 weeks.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 180
• Est. completion date: December 2021
• Est. primary completion date: December 2021
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• Informed consent given by the subject; DSM-IV-TR diagnosis of schizophrenic psychosis (295.10-30, 295.90); age 18 to 65 years, male or female; PANSS at baseline: total score = 75, proper contraception in female patients of childbearing potential; treatment with one or two antipsychotics in a stable dose of at least two weeks, body mass index between 18 and 40.

Exclusion Criteria:

• Lack of accountability; positive urine drug-screening for illicit drugs at screening (except benzodiazepines); serious suicidal risk at screening visit; other relevant interferences of axis 1 according to diagnostic evaluation (MINI); other relevant neurological or other medical disorders; pregnancy or lactation.

Related Conditions & MeSH terms

• Schizophrenia

Intervention

Other:
• endurance training
endurance training with stationary bicycles
• balance and tone program
flexibility, core strength, balance, relaxation

Locations

Country	Name	City	State
Germany	Ludwig-Maximilians-University of Munich	Munich	Bavaria

Sponsors (5)

Lead Sponsor	Collaborator
Ludwig-Maximilians - University of Munich	Central Institute of Mental Health, Mannheim, Charite University, Berlin, Germany, Heinrich-Heine University, Duesseldorf, RWTH Aachen University

Country where clinical trial is conducted

Germany, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	all-cause discontinuation	Reason of study discontinuation will be identified. The all-cause-discontinuation questionnaire will be called up 9 times from baseline up to 12 months (compare time frame) including 26 weeks of intervention and 26 weeks follow up period. Reasons are defined as (1) relevant worsening of clinical symptoms (PANSS total score above 75 on cancerous visits for more than 14 days. (2) failure to take the prescribed medication for more than 14 days. (3) Failure to comply scheduled study or diagnostic appointments for more than 6 weeks (4) Patient unavailability despite extensive efforts of the treatment team (5) Withdrawal of patient consent (6) Clinician discontinuation.	12 months (at baseline, day 14, 68, 98, 140, 182, 196, 273 and day 365)
Secondary	improvement in neurocognition (VLMT)	As part of the measurement of cognitive performance during the screening phase and at the main measurement times (at baseline, day 98, day 182 and day 365), patients and control subjects will be tested using the Verbal Learning and Memory Test (VLMT).	12 months (at baseline, day 98, day 182 and day 365)
Secondary	improvement in neurocognition (DSST)	As part of the measurement of cognitive performance during the screening phase and at the main measurement times (at baseline, day 98, day 182 and day 365), patients and control subjects will be tested using a test of verbal declarative episodic memory, the Digit Symbol Substitution Test (DSST).	12 months (at baseline, day 98, day 182 and day 365)
Secondary	improvement in neurocognition (TMT)	As part of the measurement of cognitive performance during the screening phase and at the main measurement times (at baseline, day 98, day 182 and day 365), patients and control subjects will be tested using the Trail Making Test A and B (TMT) as a test of executive functions, quick visual comprehension, attention, and processing speed.	12 months (at baseline, day 98, day 182 and day 365)
Secondary	improvement in neurocognition (B-CATS)	The partial aspect of verbal fluid from the letter Cognitive Assessment Tool for Schizophrenia (B-CATS) is also used in the neuropsychological investigation at the main measurement times (at baseline, day 98, day 182 and day 365).	12 months (at baseline, day 98, day 182 and day 365)
Secondary	improvement in neurocognition (MASC)	As part of the measurement of cognitive performance during the screening phase and at the main measurement times (at baseline, day 98, day 182 and day 365), patients and control subjects will be tested using the Facial Affect Recognition (AOP) and Theory of Mind methods. These are tasks using the Movie for the Assessment of Social Cognition (MASC).	12 months (at baseline, day 98, day 182 and day 365)
Secondary	improvement in psychopathology (PANSS)	The assessment of psychopathology on the basis of a patient interview takes place at all main measurement times. At baseline, day 98, 182 and day 365. The PANSS uses a standard procedure for assessing schizophrenia symptoms, which measures the severity of individual symptoms as well as the various symptom subgroups of positive and negative symptoms and general psychopathology.	12 months (At baseline, day 98, 182 and day 365)
Secondary	improvement in psychopathology (CGI)	The Clinical Global Impression Scale (CGI) assesses the overall symptom severity and response to interventions or therapies for psychiatric conditions to assess the effectiveness of the measures applied. It will be called up 9 times from baseline up to 12 months: At baseline, day 14, 68, 98, 140, 182, 196, 273 and day 365.	12 months (at baseline, day 14, 68, 98, 140, 182, 196, 273 and day 365)
Secondary	improvement in psychopathology (SOFAS)	The Social and Occupational Functioning Assessment Scale (SOFAS) estimates social and professional performance. It will be called up 9 times from baseline up to 12 months: At baseline, day 14, 68, 98, 140, 182, 196, 273 and day 365.	12 months (at baseline, day 14, 68, 98, 140, 182, 196, 273 and day 365)
Secondary	improvement in psychopathology (GAF)	The Social Assessment of Functioning Scale (GAF) also estimates social and professional performance. It takes place at all main measurement times. At baseline, day 98, 182 and day 365.	12 months (At baseline, day 98, 182 and day 365)
Secondary	improvement in psychopathology (BSI-53)	The Brief Symptom Inventory (BSI-53) records the symptoms using 53 items. It takes place at all main measurement times. At baseline, day 98, 182 and day 365.	12 months (At baseline, day 98, 182 and day 365)
Secondary	improvement in psychopathology (CDSS)	The Calgary Depression Scale for Schizophrenia (CDSS) measures suicidality and severity of depressive symptoms. It will be called up 9 times from baseline up to 12 months: At baseline, day 14, 68, 98, 140, 182, 196, 273 and day 365.	12 months (at baseline, day 14, 68, 98, 140, 182, 196, 273 and day 365)
Secondary	improvement in social and occupational functioning (UPSA-B)	The University of California San Diego Performance-based Skills Assessment (UPSA-B) will be used to assess the day-to-day functioning of patients with schizophrenia in the household, communications, finance, transportation, and leisure activities role play situations. It takes place at all main measurement times. At baseline, day 98, 182 and day 365.	12 months (at baseline, day 98, day 182 and day 365)
Secondary	improvement in social and occupational functioning (FROGS)	Functional Remission of General Schizophrenia (FROGS) is used as a tool to measure changes in functional levels. It takes place at all main measurement times. At baseline, day 98, 182 and day 365.	12 months (at baseline, day 98, day 182 and day 365)
Secondary	improvement in social and occupational functioning (PSP)	The Personal and Social Performance Scale (PSP) is also a tool to measure changes in functional levels. It takes place at all main measurement times. At baseline, day 98, 182 and day 365.	12 months (at baseline, day 98, day 182 and day 365)
Secondary	improvement in quality of life	Only at the beginning and end of the intervention, and after one year, is the World Health Organization's Quality of Life Questionnaire (WHOQOL-Bref) used to record quality of life (The WHOQOL Group, 1998).	12 months (at baseline, day 182 and day 365)
Secondary	improvement in body mass index (BMI)	Also, the body height (in meter) and weight (in kg) of the study participants are measured. Thereupon the BMI is calculated from the body weight (kg) divided by the square of the height (m2). The unit of BMI is kg / m2.	12 months (at baseline, day 14, 68, 98, 140, 182, 196, 273 and day 365)
Secondary	change of connectivity analysis (MRI of the brain)	At four time points, just prior to initiation of V1, V4, V6 after the end of the intervention and at V9 after the follow-up period of 6 months, structural and functional MRI (fMRI) examinations are performed on a 3 Tesla whole-body MR scanner in patients and healthy control subjects (Siemens) made.; The findings are compared with data from healthy controls and non-diseased first-degree relatives of patients with schizophrenia who have been evaluated in other BMBF-funded studies ("MooDS", "IntegraMent"). In addition, cross-sectional comparisons (TAU + Exercise vs. TAU + BKGT) and progress measurements to characterize treatment effects are planned. The measurements are divided into 2 appointments to reduce the burden on patients and subjects by the measurement time.	12 months (at baseline, day 98, day 182 and day 365)
Secondary	change of volumes of brain regions (MRI)	First, structural measurements (T1 sequence, duration: approx. 5 minutes) and investigations of the fiber connections in the brain by means of diffusion-weighted imaging (DTI, duration: approx. 10 minutes) are carried out.	12 months (at baseline, day 98, day 182 and day 365)
Secondary	change of brain function (MRI)	By means of fMRI, the tasks resting activity, working memory, episodic memory, reward processing, social perspective takeover, emotion processing as well as ability to inhibit are to be investigated with already well pre-examined tasks.; A function measurement is performed at rest without stimulation (rsMRT), which provides information on the functional networking of different brain regions at rest (duration: approx. 5 minutes). There are also three fMRI surveys that record brain activity during simple psychological tasks. - The ability to inhibit (prefrontal cortex, anterior cingulate gyrus) is examined by means of a so-called flanker task. This is to respond to a specific target stimulus, which is surrounded by either the same (congruent) or by distracting (incongruent) stimuli. - Duration: 11 minutes	12 months (at baseline, day 98, day 182 and day 365)
Secondary	improvement of endurance capacity	As part of the sports medical stress test, the determination of endurance performance in patients and control subjects takes place. For this examination, like in training, finder bike use and measurements of heart rate, lactate concentration and exertion sensation are performed. The ergometry is carried out as a Vita maxima examination, so it ends when the subjects can not or do not want to keep pedaling or when the termination criteria according to Steinacker & Liu (2002) occur. From the examination, various submaximal and maximal parameters can be determined, have the validity for endurance performance and the training intensity can be determined. The examination is carried out under standardized and safe conditions and after a detailed medical history and physical examination to exclude contraindications.; Activity meters are used to control the physical activity of study participants outside the study intervention.	12 months (at baseline, day 98, day 182 and day 365)
Secondary	change of medication and attitude of the study participants to therapy (DAI)	Also, the attitude of the study participants to therapy and medication is recorded. For this, the Drug Attitude Inventory (DAI) is used. Is takes place at the main measurement times (at baseline, day 98, day 182 and day 365).	12 months (at baseline, day 98, day 182 and day 365)
Secondary	change of medication and attitude of the study participants to therapy (SES)	The Service Engagement Scale (SES), which assesses accessibility, cooperation, help seeking and adherence, is used. It takes place at the main measurement times (at baseline, day 98, day 182 and day 365).	12 months (at baseline, day 98, day 182 and day 365)
Secondary	improvement in metabolic parameters	The laboratory diagnostic measures include a laboratory blood test, with evaluation of blood lipid levels, the C-reactive protein, glycohemoglobin (HBA1c). It takes place at the main measurement times (at baseline, day 98, day 182 and day 365).	12 months (at baseline, day 98, day 182 and day 365)
Secondary	urine (testing pregnancy and drug abuse)	Examination of the urine at baseline excludes pregnancy and drug abuse.	baseline
Secondary	gene expression	Investigation of gene expression takes place at baseline.	baseline
Secondary	change of genome-wide epigenetics	Investigation of genome-wide epigenetics takes place at the main measurement times (at baseline, day 98, day 182 and day 365).	12 months (at baseline, day 98, day 182 and day 365)
Secondary	change of proteomics	Investigation of proteomics at the main measurement times (at baseline, day 98, day 182 and day 365).	12 months (at baseline, day 98, day 182 and day 365)
Secondary	change of BDNF level	Investigation of BDNF levels at the main measurement times (at baseline, day 98, day 182 and day 365).	12 months (at baseline, day 98, day 182 and day 365)